Status: Recruiting
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.
Participants needed: 98
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangzhou University of Traditional Chinese MedicineUpdated: Jul 1, 2025Locations: 1
Eligibility criteria
Malignant tumor confirmed by histology or cytology; [+9]
Patients with diagnosed depression, obsession or/and schizophrenia; [+5]